Evidence map›Paper›PMID 29742812›Full record

ArticleHepatology (Baltimore, Md.)2018

Binding of Free and Immune Complex-Associated Hepatitis C Virus to Erythrocytes Is Mediated by the Complement System.

Kazi Abdus Salam, Richard Y Wang, Teresa Grandinetti, Valeria De Giorgi, Harvey J Alter, Robert D Allison

Abstract read
In one paragraph

Article in Hepatology (Baltimore, Md.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Kazi Abdus SalamInfectious Diseases Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD.
Richard Y WangInfectious Diseases Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD.
Teresa GrandinettiInfectious Diseases Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD.
Valeria De GiorgiInfectious Diseases Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD.
Harvey J AlterInfectious Diseases Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD.
Robert D AllisonInfectious Diseases Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD.
National Institutes of Health Clinical Center · US

Funding

A Prospective Study Of Anti-hepatitis C Virus Positive Blood DonorsZIACL002068 · CLC · CLINICAL CENTER · PI DE GIORGI, VALERIA · 2009 to 2025
$0k
Viral And Immune Factors That Influence Recovery Or Progression Of Hepatitis CZIACL002078 · CLC · CLINICAL CENTER · PI DE GIORGI, VALERIA · 2009 to 2025
$0k
HCV Infection and Innate ImmunityZIACL002121 · CLC · CLINICAL CENTER · PI DE GIORGI, VALERIA · 2009 to 2025
$0k
Intramural NIH HHS Z99 CL999999
6 · The paper itself

Abstract

Erythrocytes bind circulating immune complexes (ICs) and facilitate IC clearance from the circulation. Chronic hepatitis C virus (HCV) infection is associated with IC-related disorders. In this study, we investigated the kinetics and mechanism of HCV and HCV-IC binding to and dissociation from erythrocytes. Cell culture-produced HCV was mixed with erythrocytes from healthy blood donors, and erythrocyte-associated virus particles were quantified. Purified complement proteins, complement-depleted serum, and complement receptor antibodies were used to investigate complement-mediated HCV-erythrocyte binding. Purified HCV-specific immunoglobulin G (IgG) from a chronic HCV-infected patient was used to study complement-mediated HCV-IC/erythrocyte binding. Binding of HCV to erythrocytes increased 200- to 1,000-fold after adding complement active human serum in the absence of antibody. Opsonization of free HCV occurred within 10 minutes, and peak binding to erythrocytes was observed at 20-30 minutes. Complement protein C1 was required for binding, whereas C2, C3, and C4 significantly enhanced binding. Complement receptor 1 (CR1, CD35) antibodies blocked the binding of HCV to erythrocytes isolated from chronically infected HCV patients and healthy blood donors. HCV-ICs significantly enhanced complement-mediated binding to erythrocytes compared to unbound HCV. Dissociation of complement-opsonized HCV from erythrocytes depended on the presence of Factor I. HCV released by Factor I bound preferentially to CD19

Indexed as

Antigen-Antibody ComplexB-LymphocytesCell Line, TumorComplement System ProteinsErythrocytesFibrinogenHepacivirusHepatitis C, ChronicHumansKineticsReceptors, Complement 3bReceptors, Complement 3dAntigen-Antibody ComplexComplement System ProteinsCR1 protein, humanFibrinogenReceptors, Complement 3bReceptors, Complement 3d

Identifiers

PMID29742812
PMCPMC6226377
OpenAlexW2802182387

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.